Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
ScientificWorldJournal ; 2014: 496705, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-24977199

RESUMO

Cinobufagin (CBG), a major bioactive ingredient of the bufanolide steroid compounds of Chan Su, has been widely used to treat coronary heart disease. At present, the effect of CBG on the L-type Ca(2+) current (I Ca-L) of ventricular myocytes remains undefined. The aim of the present study was to characterize the effect of CBG on intracellular Ca(2+) ([Ca(2+)]i) handling and cell contractility in rat ventricular myocytes. CBG was investigated by determining its influence on I Ca-L, Ca(2+) transient, and contractility in rat ventricular myocytes using the whole-cell patch-clamp technique and video-based edge-detection and dual-excitation fluorescence photomultiplier systems. The dose of CBG (10(-8) M) decreased the maximal inhibition of CBG by 47.93%. CBG reduced I Ca-L in a concentration-dependent manner with an IC50 of 4 × 10(-10) M, upshifted the current-voltage curve of I Ca-L, and shifted the activation and inactivation curves of I Ca-L leftward. Moreover, CBG diminished the amplitude of the cell shortening and Ca(2+) transients with a decrease in the time to peak (Tp) and the time to 50% of the baseline (Tr). CBG inhibited L-type Ca(2+) channels, and reduced [Ca(2+)]i and contractility in adult rat ventricular myocytes. These findings contribute to the understanding of the cardioprotective efficacy of CBG.


Assuntos
Bufanolídeos/administração & dosagem , Canais de Cálcio Tipo L/fisiologia , Sinalização do Cálcio/fisiologia , Cálcio/metabolismo , Acoplamento Excitação-Contração/fisiologia , Potenciais da Membrana/fisiologia , Função Ventricular/fisiologia , Animais , Canais de Cálcio Tipo L/efeitos dos fármacos , Sinalização do Cálcio/efeitos dos fármacos , Cardiotônicos/administração & dosagem , Células Cultivadas , Acoplamento Excitação-Contração/efeitos dos fármacos , Ventrículos do Coração/citologia , Ventrículos do Coração/efeitos dos fármacos , Homeostase/efeitos dos fármacos , Homeostase/fisiologia , Ativação do Canal Iônico/efeitos dos fármacos , Ativação do Canal Iônico/fisiologia , Masculino , Potenciais da Membrana/efeitos dos fármacos , Ratos , Ratos Sprague-Dawley , Função Ventricular/efeitos dos fármacos
2.
J Pharm Pharmacol ; 69(9): 1191-1207, 2017 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-28631819

RESUMO

OBJECTIVES: The aim of this study was to examine the cardioprotective effects and latent mechanism of tannic acid (TA) on cardiac hypertrophy. METHODS: Abdominal aortic banding (AAB) was used to induce pressure overload-induced cardiac hypertrophy in male Wistar rats, sham-operated rats served as controls. AAB rats were treated with TA (20 and 40 mg/kg) or captoril. KEY FINDINGS: Abdominal aortic banding rats that received TA showed ameliorated pathological changes in cardiac morphology and coefficients, decreased cardiac hypertrophy and apoptosis, a reduction in over expressions of angiotensin type 1 receptor (AT1 R), angiotensin type 2 receptor (AT2 R), phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2) and transforming growth factor-ß (TGF-ß) mRNA, and modified expression of matrix metal proteinase-9 (MMP-9) mRNA in AAB rat hearts. Furthermore, TA treatment contributed to a decrease in malondialdehyde (MDA) and endothelin-1 (ET-1) activities and content, while it caused an increase in superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), nitric oxide (NO) and endothelial NO synthase (e-NOS). Furthermore, TA downregulated expression of tumour necrosis factor-α (TNF-α), interleukin-1ß (IL-1ß), bax, caspase-3 and upregulated expression of bcl-2. CONCLUSIONS: Tannic acid displayed obvious suppression of AAB-induced cardiac hypertrophy in rats. The cardioprotective effects of TA may be attributed to multitargeted inhibition of oxidative stress, inflammation, fibrosis and apoptosis in addition to an increase in NO levels, decrease in ET-1 levels, and downregulation of angiotensin receptors and the phosphorylation of ERK1/2.


Assuntos
Cardiomegalia/prevenção & controle , Cardiotônicos/farmacologia , Estresse Oxidativo/efeitos dos fármacos , Taninos/farmacologia , Animais , Apoptose/efeitos dos fármacos , Captopril/farmacologia , Cardiomegalia/fisiopatologia , Cardiotônicos/administração & dosagem , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Regulação para Baixo/efeitos dos fármacos , Endotelina-1/metabolismo , Fibrose/prevenção & controle , Inflamação/prevenção & controle , Masculino , Óxido Nítrico/metabolismo , Ratos , Ratos Wistar , Receptores de Angiotensina/genética , Taninos/administração & dosagem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA